Pharmabiz31m
NIH-funded intervention did not impact opioid-related overdose death rates over evaluation period
A data-driven intervention that engaged communities to rapidly deploy evidence-based practices to reduce opioid-related overdose deaths – such as increasing naloxone distribution and enhancing access ...
Pharmabiz7h
Innate Pharma announces updated results from the Sanofi developed blood cancer phase 1/2 SAR443579/IPH6101 trial
Marseille, France Tuesday, June 18, 2024, 15:30 Hrs [IST] ...
Pharmabiz9h
Indian pharma industry works on drug repurposing as AI &ML accelerating pace of novel treatments
The Indian pharmaceutical industry is now on an aggressive mode to identify drug repurposing with artificial intelligence (AI) accelerating the pace of novel treatments. Traditional drug discovery ...
Pharmabiz9h
PDMA to organise workshop on Revised Schedule M on July 13 in Pondicherry
To provide insights into the provisions of the Revised Schedule M for the pharmaceutical industries, the Pondicherry Drug Manufacturers Association (PDMA) is planning an exclusive workshop on Schedule ...
Pharmabiz7h
Rare disease patients appeal health minister to ensure sustained funding and policy intervention
Patient advocacy groups including the Rare Disease India Foundation and some of the rare disease patients have sought the new Union health minister JP Nadda to take some urgent policy decisions to ...
Pharmabiz5h
Sellas Life Sciences receives IDMC recommendation to continue phase 3 REGAL trial in acute myeloid leukaemia
Sellas Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, announced a positive review of the ongoing phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid ...
Pharmabiz1h
Aprea Therapeutics begins patient dosing in ACESOT-1051 phase 1 trial evaluating oral WEE1 inhibitor APR-1051
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, announced that the first patient has been dosed in the ACESOT-1051 phase ...
Pharmabiz15h
FDI inflow into hospitals & diagnostic centres grows 89 per cent in 2023-24
FDI inflow into hospitals & diagnostic centres grows 89 per cent in 2023-24: Gireesh Babu, New Delhi Tuesday, June 18, 2024, 08:00 Hrs [IST] The Foreign Direct Investment (FDI) eq ...
Pharmabiz8h
NW Bio announces exclusive in-license of portfolio of dendritic cell technology and intellectual property
NW Bio announces exclusive in-license of portfolio of dendritic cell technology and intellectual property: Bethesda, Maryland Tuesday, June 18, 2024, 15:00 Hrs [IST] Northwest Bio ...
Pharmabiz15h
Online registration for India Pavilion at CPhI Worldwide to open on June 19
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has announced the opening of online registration for the India Pavilion at CPhI Worldwide 2024 on June 19, 2024. CPhI Worldwide 2024 ...
Pharmabiz13h
Takeda announces positive results from phase 3 study of soticlestat in patients with Dravet syndrome and Lennox-Gastaut syndrome
Takeda announces positive results from phase 3 study of soticlestat in patients with Dravet syndrome and Lennox-Gastaut syndrome: Osaka, Japan Tuesday, June 18, 2024, 10:00 Hrs [I ...
Pharmabiz10h
Raya Therapeutic announces supportive clinical results of fasudil in amyotrophic lateral sclerosis patients
Raya Therapeutic announces supportive clinical results of fasudil in amyotrophic lateral sclerosis patients: Montreal, Canada Tuesday, June 18, 2024, 13:00 Hrs [IST] Raya Therapeu ...